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commonly used as a treatment for hematological malig-
nancies, immunodeﬁciencies, and inborn errors of me-
tabolism. HSCT is associated with several complications and
risk factors, for example graft-versus-host disease (GVHD),
viral infections, relapse, and graft rejection. Infusions of extra
lymphocytes from the original stem cell donor can be used as
a treatment after transplantation for, e.g., relapse, poor im-
mune reconstitution or secondary graft failure. The term
booster applies for infusions of donor cells without condi-
tioning. Secondary graft failure was in this study deﬁned as
initial signs of engraftment with subsequent development of
bone marrow hyperplasia requiring frequent transfusions
beyond day 60 as well as prolonged neutropenia and
thrombocytopenia. While high levels of CD3+ cells in grafts
can increase the risk for GVHD they can also promote the
graft versus leukemia (GVL) effect. In peripheral blood, 95% of
T-cells express the ab T-cell receptor and the remaining T-
cells express the gd T-cell receptor, which are not dependent
upon human leukocyte antigen (HLA) molecules for activa-
tion. As ab T-cells are the primary mediators of GVHD,
depleting them from the graft should reduce this risk, leav-
ing gd T-cells as primary Tecell type in the booster infusion.
In this pilot study, ﬁve patients transplanted with HLA-
matched related and unrelated donors were treated with ab
T-cell depleted stem cell boosts, with secondary graft failure
as primary indication. All patients also suffered from infec-
tious complications prior to the infusion, which is likely to
have been associated with the poor graft function and
development of secondary graft failure. The ab T-cell deple-
tion was performed using a CliniMACS system (Miltenyi
Biotech). Analysis of the booster infusion fraction as well as
blood samples from the patients was performed; cell char-
acterization by using ﬂow cytometry and evaluation of
chimerism as well spectratyping of gd-chains by using PCR.
Monitoring of white blood cells, platelets, and granulocytes
was carried out for 30 days post infusion. The majority of gd
T-cells in the grafts expressed Vd2 and/or Vd9. Median log
depletion of gd T-cells in the products was 3.72, and the
mean yield of gd Tecells was 84.4%. Most patients receiving
ab-depleted stem cell boosts increased their levels of white
blood cells, platelets, and/or granulocytes 30 days post
infusion. No signs of GVHD or other side effects were
detected. A larger pool of patients with longer follow-up time
is needed to conﬁrm the data in this study and compare the
treatment modality to other therapy options.177
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A major caveat of FOXP3+ T regulatory cells in immuno-
therapy against GVHD is their lownumbers in circulation and
the lack of speciﬁc cell surface markers for efﬁcient puriﬁ-
cation. DNA methylation plays a key role in the regulation of
T-cell effector function and cytokine gene expression,indicating a promising role of hypomethylating agents in
immunomodulation. Recently it was shown that in vitro
treatment of conventional T-cells with the hypomethylating
agent azacitidine (aza) induced FoxP3 expression and con-
verted CD4+CD25- cells into immunosuppressive T-cells, the
suppressor function of which is independent of FoxP3
expression (Blood 2010;116:129-139), suggesting that aza
induced suppressor function depends on the modiﬁcation of
other hypomethylated genes. Human leukocyte antigen-G
(HLA-G) is a non-classical HLA class I molecule, shown to
exert immunoregulatory functions, the expression of which
is epigenetically regulated. In this study we investigated
whether hypomethylating agents (HAs) can induce HLA-G+
immunoregulatory T cells. Negative selected T cells from
peripheral blood of healthy individuals were stimulated with
anti-CD3 plus anti-CD28 coated beads, then treated for 72
hours with aza (0.5-15 mM) in the presence of 50U/ml
inteleukin-2 (IL-2). Phenotypical characterization of aza
treated cells was performed with ﬂow cytometry. The effect
of HAs on HLA-G mRNA transcription and methylation of
upstream regulatory HLA-G gene DNA sequence was quan-
titated with Real time PCR and bisulﬁte pyrosequencing
respectively. Hypomethylation-induced HLA-G+ T cells, were
irradiated and then used as third party cells in suppression
assays. In vitro treatment of CD3+ T cells with aza induces,
dose dependent, de-novo HLA-G expression on stimulated
peripheral T cells of healthy individuals. The optimum aza
concentration for maximum HLA-G induction with the
lowest toxicity in CD3 T cells was determined at 5 mM
(surface expressing HLA-G cells: 6,883,9%, p¼0,0022, fold
increase in HLA-G mRNA relevant expression: 18,322,33).
Methylation analysis of 13CpGs revealed that treatment with
HAs caused hypomethylation of the HLA-G upstream-regu-
latory region followed by mRNA transcription and up-regu-
lation of surface protein expression. Stability assays revealed
that HLA-G expression is evident for at least 3 days after
removal of hypomethylating agent. In vitro Aza induced HLA-
G+ cells are immunosuppressive and HLA-G blocking exper-
iments further conﬁrmed that their suppressive function is
largely but not exclusively dependent on HLA-G. Phenotypic
analysis revealed that aza induced CD4+HLA-G+ are FoxP3
negative CD4lowCD25high. Conclusively, by using hypo-
methylating agent aza in vitro, we generated a CD4low-
FoxP3neg immunoregulatory population, which expresses
extracellular HLA-G and therefore can be easily isolated for
adaptive immunotherapies.178
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Novel therapeutic approaches are urgently needed for many
malignancies such as Acute Myeloid Leukemia (AML). We
have developed a new therapeutic strategy based upon NK
cell immunotherapy that exhibits high clinical potential
based upon cell and animal studies. While the harnessing of
NK cells for cellular therapy against malignancies has been a
topic of interest for several decades, our approach overcomes
a major hurdle of insufﬁcient NK cell cytotoxic activity. We
have identiﬁed that targeting the kinase GSK3 through
pharmacologic and genetic approaches leads to the hyper-
activation of human blood derived NK cells and a signiﬁcant
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S151improvement in efﬁcacy as compared to traditionally used
activated NK cells or chemotherapy in our mouse AMLmodel
systems. Importantly this GSK3 inhibition can be achieved
through a short ex vivo incubation of NK cells with a GSK3
inhibitor paving the way for a rapid implementation into a
clinical trial. Utilizing both in vitro studies with AML cell
lines (ex. OCI-AML3 and HL-60) and primary human AML
cells we observe approximately a 50% increase in efﬁcacy
with GSK3 inhibited NK cells as compared to untreated NK
cells. Further, we demonstrate signiﬁcant efﬁcacy of GSK3
inhibited NK cells in a mouse model of circulating human
AML. After 4 weekly injections of human NK cells, there is a
50% greater reduction in human AML cells present in the
mouse bone marrow with GSK3 inhibited NK cells as
compared to vehicle treated NK cells.
Besides efﬁcacy studies, our work has led a model of how
GSK3-inhibition enhances NK cell activity as depicted in
Figure 1. GSK3 inhibition leads to a dramatic increase in
adhesion of NK cells to target cells as demonstrated by a ﬂow
cytometric adhesion assay (49% vs 83% after 20 min
incubation) as well as live cell imaging. Consistent with the
increased adhesion, GSK3 inhibited NK cells as well as target
cells (after co-incubation) exhibit increased expression of
essential NK cell-target adhesion molecules including
L-selectin (on NK cells) and ICAM (on target cells). The
induction of ICAM on target cells is due to a marked
induction in TNFa production from the NK cells upon
incubation with target cells (>7 fold increase in TNFa
production). TNFa neutralization impairs the NK activity of
the GSK3 inhibited NK cells (w30%) but not vehicle treated
cells. Finally, GSK3 inhibition also leads to changes in the NK
cells that enhance activity such as increased expression ofFigure 1. Model of how GSK3 inhibition leads to hyperactive NK cells. GSK3I -
GSK3 inhibitor.granzyme and perforin and secretion of IFNg. Overall, our
work has a revealed a novel strategy for NK cell therapy that
holds high clinical potential.179
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease that destroys the motor neurons of the brain and
spinal cord. With no deﬁnitive therapy, most patients die
within 3-5 years of diagnosis. Extensive research is under-
way including the use of stem cells to regenerate damaged
neurons. Although typically an adult disease, childhood
cases are reported. Our patient began showing symptoms at
age 6 and was formally diagnosed with the rare juvenile
form of ALS at age 9. At consult, she displayed marked
spasticity with loss of ﬁnemotor control. She could not walk
or communicate verbally and required nocturnal ventila-
tory support. She was G-tube dependent for nutrition.
Because of her young age, she was ineligible for clinical
studies. After an ethics consult, FDA, IRB, and ﬁnancial ap-
provals, we followed Deda’s procedure (Cytotherapy
2009:11;18-15).
Methods, Intervention, & Analysis: Autologous, bone
marrow cells were harvested from iliac crests and
collected by Ficoll density gradient. The following day
laminectomy of C1 and partial laminectomy of C2 was
performed. A suspension of 6 million cells in 300 micro-
liters was prepared. After a 25 gauge needle was advanced
to a depth of 9 e 10 mm into the anterior horn of the
cervical spinal cord at a 20 degree angle, 500,000 cells/
50uL were injected. Six injections were performed on each
side of the midline (12 injections). Each injection was 7
mm apart on the mid-rostral caudal line and 2 mm off
midline to each other. Two strips of gel foam each infused
with 5 million cells/500uL were placed along the anterior
quadrant of the spinal cord prior to dural closure. An
additional 5 million cells/500uL were injected into the
subarachnoid space. The remainder of the cells were
injected intravenously (1.2 x 10e8 TNC/kg). There were no
postoperative complications.
Findings & Interpretation: Peak response was seen at 6
months with 12 month duration: improved phonation, facial
movements, swallowing, and upper extremity control.
Nocturnal CPAP use was successfully removed. She devel-
oped intermittent spasms/clonus with right upper extremity
pain. The patient refused additional ventilatory support and
with disease progression, died 25 months later of respiratory
failure.
Discussion & Implications: Additional studies are needed to
evaluate this therapy.
